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Background and Objective: Peri-implantitis is a destructive inﬂammatory process
characterized by destruction of the implant-supporting bone. Inﬂammasomes
are large intracellular multiprotein complexes that play a central role in innate
immunity by activating the release of proinﬂammatory cytokines. Although
inﬂammasome activation has previously been linked to periodontal inﬂamma-
tion, there is still no information on a potential association with peri-implantitis.
The aim of this study was to examine cytotoxic and proinﬂammatory eﬀects,
including inﬂammasome activation, of metals used in dental implants, in an
in vitro model, as well as from clinical tissue samples.
Material and methods: Human macrophages were exposed to diﬀerent metals
[titanium (Ti), cobalt, chromium and molybdenum] in a cell-culture assay. Cyto-
toxicity was determined using the neutral red uptake assay. Cytokine secretion
was quantiﬁed using an ELISA, and the expression of genes of various inﬂam-
masome components was analysed using quantitative PCR. In addition, the con-
centrations of interleukin-1b (IL-1b) and Ti in mucosal tissue samples taken in
the vicinity of dental implants were determined using ELISA and inductively
coupled plasma mass spectrometry, respectively.
Results: Ti ions in physiological solutions stimulated inﬂammasome activation
in human macrophages and consequently IL-1b release. This eﬀect was further
enhanced by macrophages that have been exposed to lipopolysaccharides. The
proinﬂammatory activation caused by Ti ions disappeared after ﬁltration
(0.22 lm), which indicates an eﬀect of particles. Ti ions alone did not stimulate
transcription of the inﬂammasome components. The Ti levels of tissue samples
obtained in the vicinity of Ti implants were suﬃciently high (≥ 40 lM) to stimu-
late secretion of IL-1b from human macrophages in vitro.
Conclusion: Ti ions form particles that act as secondary stimuli for a proinﬂam-
matory reaction.
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Hundreds of thousands of patients
worldwide are treated with dental
implants each year (1,2). Dental
implants were ﬁrst introduced by
Branemark in the 1960s and are cur-
rently the standard treatment for sin-
gle tooth loss and for partially and
total edentulous patients (3–5). The
treatment is most reliable for restor-
ing edentulism, with reported success
rates of more than 90% (6–9). How-
ever, in recent years reports have
shown increasing numbers of patients
with peri-implantitis, resulting in bone
loss around implants. The reported
prevalence of peri-implantitis ranges
from 11.2% to 53% for subjects and
from 4.7% to 36.6% for implants
(10–18). The substantial variability of
the estimated prevalence of peri-
implantitis reported in the literature
indicates that either there is a true dif-
ference in diﬀerent cohorts of patients
or the true prevalence of peri-implan-
titis is not yet known. One of the rea-
sons for this large discrepancy is the
inconsistent criteria in the deﬁnition
of peri-implantitis.
At the ﬁrst European Workshop on
Periodontology in 1993 it was agreed
that the term peri-implantitis should
be used speciﬁcally for destructive
inﬂammatory processes around
osseointegrated implants in function
that lead to peri-implant ‘lesion’ for-
mation and the loss of supporting
bone (19).
It is hypothesized that the inﬂamma-
tory response around osseointegrated
implants is an immune response pro-
duced against oral bacteria to prevent
them establishing a bioﬁlm on the
implant surface (18,20,21). The
immunopathological events that gov-
ern peri-implantitis resemble those of
periodontitis, yet they are considerably
more pronounced (22). The bioﬁlm
microbiota associated with peri-
implantitis shows strong similarities to
periodontitis, yet recent metagenomic
analyses may also reveal some distinc-
tive diﬀerences between the two (23).
Of special note regarding the pathogen-
esis of peri-implantitis, Albrektsson et
al. (24) propose that it largely accounts
for an immunological foreign-body
response to titanium, a hypothesis
which awaits further investigation.
The deﬁnition of peri-implantitis by
Albrektsson & Isidor (19) is still used,
but there is no clear distinction
between slight, moderate and severe
peri-implantitis. Severe periodontitis is
reported to have a global prevalence of
11% on global basis (25,26) and proba-
bly peri-implantitis will show about the
same prevalence as more research data
become published in the literature.
Atieh et al. (27) reported, in a review
based on 504 identiﬁed studies, esti-
mates for the frequency of peri-implant
mucositis of 63.4% for participants
and 30.7% for implants and for the
frequency of peri-implantitis of 18.8%
for participants and 9.6% for impl-
ants. An even higher frequency of the
occurrence of peri-implant diseases was
recorded for smokers, with a sum-
mary estimate of 36.3%. These preva-
lence numbers show that peri-implant
mucositis and peri-implantitis are not
uncommon in patients undergoing den-
tal implant treatment and should not
be neglected, especially in high-risk
patients.
In comparison with orthopedic
implants that are placed in a sterile
environment and accordingly should
not be exposed to bacteria or bacte-
rial products, dental implants are
exposed to the environment of the
mouth. However, orthopedic implants
induce an inﬂammatory response,
similar to that of peri-implantitis,
around dental implants, and loss of
orthopedic implants are described in
the literature as aseptic loosening, ﬁrst
reported by Harris et al. (28). Aseptic
loosening of an orthopedic prosthesis
is one of the most frequent complica-
tions leading to a revision of the pros-
thesis, and much research has been
carried out during the last 10 years to
identify the mechanism of the perio-
prosthetic osteolysis leading to failure
of the prosthesis (29–32).
The alarm cytokine, interleukin
(IL)-1b, possesses a wide spectrum of
inﬂammatory, metabolic, physiologic,
hematopoietic and immunologic prop-
erties and plays a crucial role in the
innate immune system (33). When the
toll-like receptors on macrophages are
activated by pathogen-associated
molecular patterns, production of
pro-IL-1b in cytoplasm is initiated
and upon a secondary stimulation
that involves inﬂammasome activa-
tion, ﬁnally active IL-1b can be pro-
cessed and secreted (34–36). Release
of active IL-1b initiates inﬂammation,
leading to inﬁltration of leukocytes to
eliminate the infectious agents (37).
IL-1b is perhaps one of the most
potent cytokines, causing inﬂamma-
tion and fever, and also induces
expression of proinﬂammatory genes
that encode IL-6 and nitric oxidase
synthase, and increases expression of
adhesion molecules, promoting leuko-
cyte migration from the bloodstream
into the infected tissue (37–39).
Activation and release of IL-1b is
mediated by the assembly of a cytoso-
lic multimer consisting of NLR family,
pyrin domain containing 3 (NLRP3),
apoptosis-associated Speck-like Pro-
tein Containing a Card (ASC) and
pro-caspase-1, named the NLRP3
inﬂammasome (40). Activation of the
NLRP3 inﬂammasome results in active
caspase-1 that stimulates release of
mature IL-1b from macrophages
would be more accurate, which can
occur from both pathogen-associated
molecular patterns and damage-asso-
ciated molecular patterns (40,41). It
has been shown that diﬀerent com-
pounds, such as ﬂagellin, double-
stranded DNA and various crystals
(asbestos, alum, silica, cholesterol and
uric acid), can mediate activation and
release of mature IL-1b (42–48). More-
over, a newly discovered mechanism of
cell death, termed pyroptosis, leads to
activation speciﬁcally of caspase-1
(49). The term pyroptosis is now
accepted as a death mechanism, and
macrophages undergoing pyroptosis
show signs of both apoptosis and
necrosis with speciﬁc activation of cas-
pase-1 (50). Caspase-1 is responsible
for activation of pro-IL-1b, pro-IL-18
and pro-IL-33 to their active forms
and secretion (51,52). Several bacterial
products, such as lipopolysaccharide
(LPS), are known to increase expres-
sion of pro-IL-1b in macrophages (53).
However, a secondary stimulus is
needed to induce secretion of a high
level of bioactive IL-1b. This activation
can be induced by various bacterial
species through activation of the
inﬂammasome complex, caspase-1 acti-
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vation and ultimately IL-1b secretion
(54). This secondary activation can be
induced by direct interactions of bacte-
ria or bacterial components with the
inﬂammasome complex (such as for
Salmonella typhimurium or Francisella
tularensis) or through cell-surface inter-
actions (such as for Listeria monocyto-
genes, Staphylococcus aureus,
Aggregatibacter actinomycetemcomi-
tans or Porphyromonas gingivalis) (54–
60).Oral bioﬁlms are also shown to reg-
ulate expression of the inﬂammasome
complexes (61), and expression of
NLRP3 inﬂammasome in gingival tis-
sue is shown to be increased in peri-
odontal disease, compared to healthy
periodontal conditions (59).
Caicedo et al. (62) showed that
soluble and particulate forms of
cobalt–chromimum–molybdenum (Co
–Cr–Mo) alloys activate the NLR
family, pyrin domain containing 3
inﬂammasome danger-signaling path-
way in human macrophages, leading to
secretion of IL-1b. Recently published
data suggest that sodium ﬂuoride cor-
rodes titanium (Ti) implants, and the
release of Ti ions is suggested to acti-
vate factors of importance for bone
resorption (63). As previously shown
by our group, rapid degradation of the
tooth-supporting tissues in young indi-
viduals is associated with the presence
of highly leukotoxic A. actinomycetem-
comitans (64). The leukotoxin pro-
duced by this bacterium activates the
inﬂammasome complex and caspase-1
in human macrophages, and conse-
quently stimulates activation and
release of IL-1b (56). Aggregatibac-
ter actinomycetemcomitans is also
shown to activate the expression of
NLRP3 and down-regulate the expres-
sion of NLRP6 in human mononuclear
cells (60).
In the present study, we hypothe-
size that materials released from den-
tal implants and overlaying dental
constructions contribute to the inﬂam-
matory reactions associated with
peri-implantitis by stimulating inﬂam-
masome activation and IL-1b secretion
in macrophages. We show that Ti ions
form particles in a physiological solu-
tion and induce a proinﬂammatory
reaction in human macrophages
in vitro. In addition, this activation is
caused by the increased Ti concentra-
tion that could be detected in samples
of tissue taken in close vicinity to
dental implants.
Material and methods
Growth medium and cell culture
A human acute monocytic leukemia
cell line THP-1 (ATCC TIB-202TM)
was purchased from the American
Type Culture Collection (ATCC;
Manassas, VA, USA) and cultured in
RPMI 1640 containing 10% fetal
bovine serum (FBS) with a supple-
ment of penicillin–streptomycin
(Sigma-Aldrich; St Louis, MO, USA).
The THP-1 cell line originates from
an anonymous 1-year-old infant boy
with acute monocytic leukemia.
Buﬀy coats (enriched leukocyte frac-
tion) were obtained from heparinized
venous blood, taken from healthy
donors at Norrlands University Hospi-
tal blood bank (Umea, Sweden).
Informed written approval was given
by all subjects, and authorization for
the study was granted by the Human
Studies Ethical Committee of Umea
University, Sweden (§67/3, dnr 03–
019). Mononuclear lymphocytes were
isolated from buﬀy coat with isopycnic
centrifugation in LymphoprepTM (Axis-
Shield, Oslo, Norway), as ﬁrst descri-
bed by Boyum (65). The mononuclear
leukocyte-containing fraction was col-
lected, centrifuged at 220 g for 5 min
and washed in phosphate-buﬀered sal-
ine three times to remove platelets.
The cell pellet was resuspended in
the growth medium RPMI 1640, con-
taining 10% FBS with a supplement
of penicillin–streptomycin (Sigma-
Aldrich), to a cell concentration of
5 9 106 cells/mL.
The suspension was distributed into
a 24-well culture plate (Nunc A/S,
Roskilde, Denmark), at 1 mL/well,
and was incubated at 37°C under 5%
CO2 for 2 h to allow the monocytes to
adhere. The nonadherent lymphocytes
were removed by two rinses with 1 mL
of phosphate-buﬀered saline. The cul-
ture plate was put on ice to detach
adherent cells, which were thereafter
harvested by centrifugation (220 g for
5 min) and resuspended in growth
medium to a concentration of 4 9 106
cells/mL. The adherent cells consisted
of approximately 95% monocytes, in a
total number of about 106 cells/well.
Stimulation agents
Plasma standard solution, Specpure,
1000 lg/mL, for Co, Cr, Ti and Mo,
was purchased from Alfa Aesar
GmbH & Co.KG (Karlsruhe, Ger-
many). Plasma standards have a con-
tent of acid to stabilize the metal in
an ionic form, Cr in 5% HCl for Cr;
5% nitric acid (HNO3) for Co; and
5% HNO3/trace (tr). hydrogen ﬂuor-
ide (HF) for Ti and Mo.
Measurement of acidity was deter-
mined with a pH meter (Beckman),
and ion solutions of Co, Cr, Ti and
Mo were adjusted to pH 7.2 with 1 M
NaOH and diluted to a concentration
of 1600 lM in RPMI 1640.
Filtration
Filtration of soluble Co, Cr, Ti and
Mo was carried out through a 0.22-
lm sterile ﬁlter (Merck Millipore, Bil-
lerica, MA, USA). A solution of
1000 lM in cell-growth medium
RPMI 1640 + 10% FBS was mixed
and divided into three groups, as fol-
lows: unﬁltered; ﬁltered after 1 h; and
ﬁltered after 24 h. Samples of the test
solutions were sent to ALS Scandi-
navia AB, Lulea, Sweden, for mea-
surement of the Ti content.
After the pilot test with ﬁltering of
the solutions, it was decided to only test
ﬁltration of Ti for cell stimulation. The
Ti solution was divided in two groups:
one group was unﬁltered with a concen-
tration range of 0–400 lM; and in the
other group the solution was ﬁltered
through a 0.22-lm sterile ﬁlter (Merck
Millipore) to determine whether Ti ions
suspended in RPMI 1640 form parti-
cles. THP-1 cells were then exposed to
the ﬁltered and unﬁltered Ti solutions,
according to the protocol for cell stimu-
lation described above.
Clinical samples
Three patients, treated 5 years previ-
ously with a ﬁxed full-arch implant
bridge supported by six Nobel Bio-
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care (Z€urich, Switzerland) Mark III
regular platform Branemark implants,
were randomly selected consecutively
by their surname.
A clinical examination was per-
formed and all implants were evaluated
and graded as healthy/peri-implant
mucositis/peri-implantitis, according
to the classiﬁcation by Albrektsson and
Isidor (19). Two deep soft-tissue biop-
sies were taken from each patient in
close vicinity to the implant. The
biopsy sites were selected, after clinical
examination, at the clinically healthiest
implant and at an implant showing
signs of inﬂammation. Samples of the
crevicular ﬂuid were collected from the
peri-implant pocket at the biopsy sites,
before taking biopsy samples, for IL-
1b quantiﬁcation, as described by
Gamonal et al. (66). The sample areas
were isolated with cotton rolls and
gently dried with an air syringe before
collection of the peri-implant crevicular
ﬂuid (PICF) to avoid contamination
from saliva. A standard ﬁlter paper
strip was used as absorbent and gently
inserted into the peri-implant pocket
and left for 30 s to collect the PICF
sample. After collection of the PICF,
the strip was put into a sterile Eppen-
dorf tube and sent to the laboratory for
analysis within 1 h and the protein was
eluted as described by Kelk et al. (57).
After collection of PICF, a bioﬁlm
sample was taken from the same sites
by inserting a sterile paper point into
the peri-implant pocket for 30 s. After
collection, the paper point was placed
into a viability-preserving microbio-
static, anaerobic (VMGAIII) transport
medium supplemented with Nystatin
(2 mg/L), as described earlier (67). Eth-
ical approval (Dnr 2011-405-31M) for
the biopsies and biological samples
from patients were obtained from the
Regional Ethical Review Board at
Umea University, Sweden.
Cell stimulation
One-hundred microliters of THP-1
cells suspended in RPMI 1640 were
distributed in a 96-well culture plate
at a cell concentration of 106 cells/mL.
Phorbol 12-myristate 13-acetate
(Sigma-Aldrich) was added to a con-
centration of 50 nM, and the cells were
incubated at 37°C under 5% CO2 for
24 h, to diﬀerentiate THP-1 cells
toward the macrophage phenotype.
Lipopolysaccharides from Escheri-
chia coli (E. coli LPS) were purchased
from Sigma-Aldrich. After 24 h of cul-
ture at 37°C under 5% CO2, THP-1
cells were primed with 100 ng/mL of
E. coli LPS for 6 h. Growth medium
was then replacedwith 100 lL ofRPMI
1640 containing the stimulatory agents,
Co, Cr, Ti or Mo at the highest concen-
tration (800 lM) and serially diluted to
concentrations of 400, 200, 100, 50, 25,
12.5, 6.3, 3.1 and 0 lM. Cells were
exposed to these agents for 24 h and
then the experiment was terminated. To
determine if stimulation with the metals
activates secretion of IL-1b through
activation of the NLRP3 inﬂamma-
some, a known caspase-1 inhibitor, Ac-
YVAD-CMK (Calbiochem Merck
KGaA, Darmstadt, Germany), was
added in some of the in vitro experi-
ments with THP-1 cells.
RNA extraction and cDNA synthesis
Once the exposure period was com-
plete, the cell culture supernatants were
removed by centrifugation, whereas the
cell pellets were washed twice in phos-
phate-buﬀered saline and lysed. Total
RNA was extracted using the RNeasy
Mini Kit (Qiagen, Venlo, the Nether-
lands) according to the manufacturer’s
instructions. The RNA concentration
was measured spectrophotometrically,
and 400 ng of total RNA was reverse
transcribed into cDNA by using the
High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems,
Foster City, CA, USA) in a volume of
20 lL. The resulting cDNA was stored
at20°C until further use.
Quantitative real-time polymerase
chain reaction
For gene-expression analyses, quanti-
tative real-time PCR (qPCR) was per-
formed using a Step One Plus Real
Time PCR System (Applied Biosys-
tems). For the ampliﬁcation reactions,
the TaqMan Gene Expression Master
Mix and Gene Expression Assay kits
from Applied Biosystems were used
(assay IDs: NLRP3: Hs00918085-m1;
ASC: Hs01547324-m1; CASP1:
Hs00354836-m1; IL1b: Hs00174097-
m1; and GAPDH: Hs99999905-m1).
The standard PCR conditions were
10 min at 95°C, followed by 40 cycles
at 95°C for 15 s and 60°C for 1 min.
The expression levels of the target
transcripts in each sample were calcu-
lated by the comparative cycle thresh-
old (Ct) method (2
DCt formula) after
normalization to the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)
housekeeping gene.
Cytotoxicity
In vitro cytotoxicity of the stimulatory
agents on THP-1 cells at the concentra-
tions tested was measured using the
neutral red uptake assay, following the
protocol described by Repetto et al.
(68). The neutral red uptake assay is a
simple technique used to quantify the
proportion of viable cells in culture by
addition of the dye neutral red
(3-amino-7-dimethylamino-2-methyl-phe-
nazine hydrochloride) (Sigma-Aldrich),
which is incorporated and accumulated
in the lysosomes of viable cells. After
24 h of exposure of THP-1 cells to
stimulants, the supernatant was
removed and the neutral red assay was
performed on the cells. The absorbance
of the extracted neutral red from the
challenged cells was read in a spec-
trophotometer at a wavelength at
540 nm, using the blank without cells
as the reference.
Cytokine analyses with ELISA
A “sandwich” ELISA (the Human IL-
1b DuoSet ELISA; R&D Systems, Inc.
Minneapolis, MN, USA) was used to
analyze the cell culture supernatant to
detect IL-1b secretion by THP-1 cells
and human primary monocytes after
stimulation with E. coli LPS and
metals. After 24 h of exposure of the
cells, the supernatant was removed and
the ELISA was performed following
the protocol provided by the manufac-
turer. A spectrophotometer measuring
a wavelength of 450 nm was used to
quantify the amount of IL-1b secreted
into the supernatant. A human multi-
analyte ELISArray from SABio-
sciences Corporation (Frederick, MD,
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USA) was performed as a screen on
primary human monocytes exposed to
Ti ions. Cytokines analyzed in the
screening were IL-1a, IL-1b, IL-2, IL-
4, IL-6, IL-8, IL-10, IL-12, IL-17a,
interferon gamma, tumor necrosis fac-
tor alpha and granulocyte–macro-
phage colony-stimulating factor.
Inductively coupled plasma mass
spectrometry
Inductively coupled plasma mass spec-
trometry was ﬁrst introduced by Houk
et al. (69) and ﬁrst commercialized by
PerkinElmer (Waltham, MA, USA) in
1983. Samples were prepared by mix-
ing approximately 0.02 g of lyophi-
lized tissue material with 2 mL of
nitric acid for trace analysis (Sigma
Aldrich) in high-pressure reaction ves-
sels with Teﬂon micro sampling
inserts. Digestion of the samples was
then performed on an Ethos 1 micro-
wave digestion system (Milestone, Sor-
isole, Italy) employing a microwave
program reaching 180°C within 5 min
and then held at 175–185°C for
10 min. The resulting clear solutions
were transferred into acid-washed sam-
ple tubes together with 4 mL of HNO3
that was used to rinse the inserts. The
samples were then diluted 10 times
with ultrapure Milli-Q water (Milli-
pore) before the elemental analysis was
conducted on a 7700 Series ICP-MS
system (Agilent Technologies; Santa
Clara, CA, USA) operated in both the
no gas mode and the helium (He)
mode using indium as an internal stan-
dard added online. The instrument
was calibrated with Ti standard solu-
tions prepared from a 1000 lg/mL Ti
standard (Ultra Scientiﬁc; North
Kingstown, RI, USA) and 2% HNO3
in Milli-Q water within the range 100–
2000 ng/L. The Ti concentrations mea-
sured were adjusted for the average
concentration measured for blanks
prepared in the same way as the sam-
ples, but with no biological material
added, and the elemental content was
ﬁnally reported as lM in tissue.
Statistical analysis
The statistical signiﬁcance of diﬀer-
ences was evaluated using one-way
ANOVA and two-way ANOVA,
using Sidak correction and Dunnett’s
test for multiple comparisons. The
data were considered signiﬁcant at
p ≤ 0.05.
Results
Proinflammatory activation in
cultures of primary monocytes
The proinﬂammatory eﬀect of Ti was
studied in cultures of primary mono-
cytes isolated from peripheral blood.
A multi-analyte ELISA was employed
to screening the eﬀects on the cytoki-
nes IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-
8, IL-10, IL-12, IL-17a, interferon-c,
tumor necrosis factor alpha and gran-
ulocyte–macrophage colony-stimulat-
ing factor. The monocyte cultures
were primed for 6 h, with or without
E. coli LPS (100 ng/mL), and exposed
to Ti (25 lM) for 24 h. This screening
experiment was performed once and
analyzed in duplicate, in accordance
with the manufacturer’s protocol
(SABiosciences Corporation). The
eﬀect of the metal alone on the secre-
tion of all the cytokines studied was
limited, while LPS priming enhanced
secretion of IL-1b, IL-6, IL-8, IL-10,
interferon-c and granulocyte–macro-
phage colony-stimulating factor
(Fig. 1). The presence of the metal
enhanced the secretion of IL-1b in the
monocyte cultures that were primed
with E. coli LPS. The eﬀect of diﬀer-
ent metals (Co, Cr, Ti and Mo) at
low concentrations (≤ 25 lM) on the
secretion of IL-1b from primary
monocytes was further estimated
using conventional ELISA. The
results obtained after 24 h of expo-
sure of the monocytes to the diﬀerent
metals, with or without priming with
E. coli LPS (6 h, 100 ng/mL), further
conﬁrmed that the eﬀect on IL-1b
secretion of the metals alone was lim-
ited, whereas an enhanced eﬀect was
documented in combination with LPS
priming of the target cells (Fig. 2A–
D). Ti acted as a secondary stimulus
in cultures of LPS-primed (primary
stimuli) human macrophages, result-
ing in activation and secretion of IL-
1b.
Gene-expression analyses of
inflammasome components
The eﬀects of the diﬀerent metals
(Co, Cr, Ti and Mo) on gene expres-
sion of the inﬂammasome components
Fig. 1. Screening test with multi-analyte data of cytokine secretion from macrophages iso-
lated from peripheral blood and exposed to titanium (Ti) (for 24 h), with or without prim-
ing with Escherichia coli lipopolysaccharide (LPS) (6 h). Mean results of duplicates from
one experiment are shown. GM-CSF, granulocyte–macrophage colony-stimulating factor;
IFN-c, interferon-c; IL, interleukin; TNF-a, tumor necrosis factor-a. Arrows indicates
enhanced values caused by Ti shown in the inserted diagram.
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NLPR3, Caspase-1, ASC and IL-1b
in human primary monocytes, were
measured with qPCR. Monocyte cul-
tures, with or without 6 h of priming
with E. coli LPS (100 ng/mL), were
exposed to Co, Cr, Ti and Mo at con-
centrations of 5 and 25 lM for 24 h.
Neither the exposure to the diﬀerent
metals nor priming with E. coli LPS
induced any enhanced expression of
NLRP3, ASC or CASP1 genes
(Fig. 3A–C). In contrast, the expres-
sion of IL-1b was enhanced after
priming with LPS and was further
stimulated by exposure to the diﬀer-
ent metals (Fig. 3D).
Cytotoxicity and proinflammatory
activation in macrophage cultures
(THP-1 cells)
The cytotoxicity of Co, Cr, Ti and Mo
was examined by adding diﬀerent
concentrations of these metal ions to
cultures of phorbol 12-myristate
13-acetate-diﬀerentiated THP-1 cells
primed for 6 h with E. coli LPS
(100 ng/mL). After 24 h of exposure,
neither Co nor Cr had any eﬀect on via-
bility at concentrations of ≥ 200 lM,
and Ti andMo caused reduced viability
(Fig. 4). However, at concentrations
≥ 100 lM, Ti completely lacked any
cytotoxic eﬀect in this cell-culture
assay. An enhanced secretion of IL-1b
could be detected in the samples with
reduced viability and also at sub-toxic
concentrations of Ti (Fig. 4C). IL-1b
secretion was reduced in the presence
of a caspase-1 inhibitor (Ac-YVAD-
cmk; 100 lM) with the most pro-
nounced eﬀect observed in the cell
cultures exposed to Ti (Fig. 4). Priming
of the THP-1 cells with E. coli LPS
(100 ng/mL for 6 h) before exposure to
Ti caused a ﬁve-fold increase in IL-b
secretion, without interfering with the
cytotoxic eﬀect of the metal solution
(Fig. 5). A statistically signiﬁcantly
(p < 0.001) higher secretion of IL-1b
was found in cells exposed to both Ti
and E. coli LPS, and this eﬀect was
dose dependent.
Effect of filtration
The proinﬂammatory activation
caused by Ti in cultures of phorbol
12-myristate 13-acetate-diﬀerentiated
E. coli LPS-primed (100 ng/mL for
6 h) THP-1 cells disappeared after ﬁl-
tration (0.22 lm), whereas the cyto-
toxic eﬀect of the ﬁltered solution
persisted (Fig. 6). The solution of
A
B
C
D
Fig. 2. Secretion of interleukin (IL)-1b from macrophages isolated from peripheral blood
and exposed to solutions of 0, 5 or 25 lM of cobalt (Co), chromium (Cr), titanium (Ti) or
molybdenum (Mo) (for 24 h), with and without priming with Escherichia coli lipopolysac-
charide (LPS) (for 6 h). (A) Macrophages exposed to Co solution. (B) Macrophages
exposed to Cr solution. (C) Macrophages exposed to Ti solution. (D) Macrophages
exposed to Mo solution. *p < 0.05, **p < 0.01 or ***p < 0.001.
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400 lM Ti in RPMI 1640 with 10%
FBS had lost 94.4% of the Ti when
ﬁltered after 24 h, as analyzed using
ICP-MS (Fig. 7). This indicates that
the stimulation of IL-1b secretion in
cultures of primed THP-1 cells is
caused by particles formed in the cell-
culture medium, whereas the cytotoxic
eﬀect of Ti is an eﬀect of free soluble
ions. Filtration of solutions of the
other metals tested (Co, Cr and Mo)
did not change the concentration of
the metals in these solutions, which
indicates that no particle or complex
that is unable to pass through a 0.22-
lm ﬁlter was formed in these solu-
tions (data not shown).
Analyses of human biopsies and
PICF
Gingival mucosal biopsies were taken
from three randomly selected patients.
Clinical evaluation of the peri-implant
mucosa showed that two implant sites
were graded as healthy, two sites as
mucositis and two sites as peri-
implantitis (Table 1). The ICP-MS
analyses showed that the Ti concen-
tration in human biopsies varied from
7.3 to 38.9 lM. These levels of Ti in
the peri-implant mucosa were within
the levels that give a proinﬂammatory
response in vitro. PICF samples from
the peri-implant pockets showed an
IL-1b range from 13.0 to 268.9 pg/
mL (Table 1).
Aggregatibacter actinomycetemcomi-
tans was detected in three out of six
samples from the peri-implant pockets
(Table 1). No conclusion could be
drawn of the correlations between the
concentrations of Ti, the IL-1b level,
the presence of A. actinomycetem-
comitans and clinical data.
Discussion
This study evaluated the proinﬂam-
matory eﬀect in human macrophages
exposed to Ti particles formed in cell
growth medium, and the synergetic
eﬀect achieved when the macrophages
were exposed to bacterial components
(i.e. E. coli LPS) before exposure to
Ti. In addition, the amount of Ti
found in human tissue surrounding a
dental implant was evaluated and
compared with the concentrations
found to activate and secrete IL-1b
in vitro.
It was demonstrated that Ti ions
form particles in cell growth medium
and that the activation and secretion
of IL-1b was correlated to particles
and not to the soluble ions. Filtration
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Fig. 3. Gene expression in human macrophages isolated from peripheral blood, with and
without Escherichia coli lipopolysaccharide (LPS) priming (for 6 h), after exposure for
24 h to cobalt (Co), chromium (Cr), titanium (Ti) or molybdenum (Mo) at concentrations
of 5 and 25 lM. Expression of the diﬀerent NLR family, pyrin domain containing 3
(NLRP3)-associated components was calibrated against that of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH). (A) NLRP3 expression. (B) Apoptosis-associated Speck-
like Protein Containing a Card (ASC) expression. (C) CASP1 expression. (D) Interleukin
IL-1b expression. *p < 0.05.
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of the Ti solution abolished its proin-
ﬂammatory eﬀect on the macro-
phages, whereas the ﬁltrate retained
its cytotoxicity that occurred at higher
concentration of ions. This is in con-
trast to earlier report by Caicedo
et al. (70) showing that soluble ions,
more than particles, are responsible
for the proinﬂammatory response
induced in monocytes/macrophages.
Data published by Wachi et al. (63)
suggest that Ti ions at a concentra-
tion of 9 p.p.m. increase the ratio of
RANKL/osteoprotegerin. This con-
ﬁrms our ﬁndings that Ti ions
increase the secretion of bioactive IL-
1b from macrophages, which is a
cytokine that stimulates bone resorp-
tion through activation of RANKL
expression (71). In addition, our
results indicate that it is Ti-formed
particles, not the ionic form of Ti, as
suggested by Wachi et al. (63), which
stimulate a proinﬂammatory response.
In the present study, a proinﬂamma-
tory eﬀect could be found also for
Mo, but not for Co and Cr, and ﬁl-
tration of Co, Cr and Mo solutions in
cell-culture medium did not cause any
reduction in the metal concentrations.
This ﬁnding, that soluble Mo
induces a macrophage proinﬂamma-
tory response, is in line with that pre-
viously reported by Caicedo et al.
(70).
In the literature it is now accepted
that two distinct signals are needed
for expression, activation and release
of active IL-1b, namely a primary sig-
nal and a secondary signal (72). Our
results indicate that Ti particles seem
to work as a secondary stimulus, acti-
vating the inﬂammasome in the
macrophages, resulting in the release
of active IL-1b from cells. Diﬀerent
kinds of stimuli (danger-associated
molecular patterns) have been found
to act as a secondary stimulus and
cause inﬂammation (42,73–75). It has
previously been shown that non-
degradable TiO2 nanoparticles phago-
cytized in pulmonary tissue activate
the NLPR3 inﬂammasome through
reactive oxygen species, causing the
same inﬂammation in the lung as seen
in patients with asbestosis (76–78).
This indicates that the proinﬂamma-
tory eﬀect caused by the formed Ti
particles in the present study is trig-
gered by frustrated phagocytosis,
leading to inﬂammasome activation
and release of bioactive IL-1b.
Escherichia coli LPS works as a pri-
mary stimulus, resulting in an up-regu-
lation in the expression of pro-IL-1b
and accumulation of pro-IL-1b intra-
cellularly in macrophages. A secondary
stimulus is necessary for the activation
and release of mature IL-1b, through
the inﬂammasome-mediated activation
A
B
C
D
Fig. 4. THP-1 cells primed with Escherichia coli lipopolysaccharide (LPS) (100 ng/mL) for
6 h and exposed to cobalt (Co), chromium (Cr), titanium (Ti) or molybdenum (Mo) ions
for 24 h. Each bar chart shows release of interleukin (IL)-1b pg/ml, with or without cas-
pase-1 inhibitor. Viability is shown as (%) viable cells in the line chart. (A) Co. (B) Cr.
(C) Ti. (D) Mo. ***p < 0.001.
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of caspase-1 (76–78). We have previ-
ously shown that the leukotoxin of
A. actinomycetemcomitans induces an
abundant release of bioactive IL-1b
from macrophages that have been
prestimulated with bacterial compo-
nents (57). This is in line with the ﬁnd-
ings in the present study showing that
the eﬀect of Ti alone on IL-1b release
from macrophages is negligible com-
pared with that found in macrophage
cultures pre-exposed to microbial
stimuli.
Quantitative gene-expression analy-
ses of macrophage cultures exposed to
sub-toxic concentrations of metal ions
showed that the metals, either alone
or with pre-incubation with E. coli
LPS, do not stimulate the expression
of mRNA for the inﬂammasome com-
ponents ASC, NLRP3 or CASP1. In
contrast, the expression of pro-IL-1b
was enhanced by prestimulation with
LPS, and further enhanced by a sec-
ondary stimulation with the diﬀerent
metal ions. The lack of eﬀect of the
secondary stimulants on gene expres-
sion has previously been demon-
strated for the periodontitis-associated
A. actinomycetemcomitans leukotoxin
(64). It was also previously shown
that A. actinomycetemcomitans could
up-regulate expression of the NLRP3
inﬂammasome in human mononuclear
cells (60).
IL-1b is a key molecule in tissue
remodeling and enhanced levels of
this molecule are found in tissue ﬂuids
of degenerative diseases, such as peri-
odontitis and peri-implantitis (79,80).
The reduced release of active IL-1b in
experiments performed in the presence
of a caspase-1 inhibitor indicates that
the formed Ti particles act through
the NLRP3 inﬂammasome.
Our results show that Ti concentra-
tions found in peri-implant mucosa
located in close vicinity to the
implants contain similar concentra-
tions of the metal that induces the
activation and secretion of IL-1b
in vitro. The analyses of metal per-
formed on the peri-implant mucosa
could not distinguish between parti-
cles and soluble ions in the sample. In
addition, only three patients were
examined in the present study, and
further investigations are needed to
Fig. 5. Interleukin (IL)-1b concentration (pg/ml) in culture medium of THP-1 cells with
and without priming with Escherichia coli lipopolysaccharide (LPS) (100 ng/mL for 6 h),
and exposed for 24 h to titanium (Ti) solution in a concentration range from 0–800 lM, is
shown. The line chart shows the viability (%) of the cells exposed to the stimulating agent.
Values represent mean  SD of three experiments. **p < 0.01 or ****p < 0.0001.
Fig. 6. Secretion of interleukin (IL)-1b from THP-1 cells primed with Escherichia coli
lipopolysaccharide (LPS) (100 ng/mL) for 6 h and exposed to a ﬁltered or unﬁltered solu-
tion of titanium (Ti) for 18 h at a concentration range of 0–800 lM. Viability (%) is
shown in the line chart. *p < 0.05, **p < 0.01 or ****p < 0.0001.
Fig. 7. Reduction of titanium (Ti) concentration in RPMI 1640 with 10% fetal bovine
serum (FBS) after ﬁltration through a 0.22-lm ﬁlter, 10 min and 24 h after addition of
the Ti solution to a ﬁnal concentration of 400 lM. The Ti concentration in the unﬁltered
stock solution was set to 100%. Ti concentration was measured by inductively coupled
plasma mass spectrometry (ICP-MS).
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ﬁnd if there is a correlation between
metal content and periodontal inﬂam-
mation promoting peri-implantitis.
The true cause of peri-implantitis is
highly discussed in the dental commu-
nity. Probably there is a diﬀerence
between periodontal and peri-implant
disease, although clinical and radiolog-
ical signs of the diseases have much in
common. However, there are signiﬁ-
cant histological discrepancies, which
may explain the diﬀerences in the onset
and progression of the diseases (22,81).
Recent research suggests that bone
loss surrounding an implant is not
induced by microbes, but is more
likely to be a foreign body reaction
against the implant (24,82). Our pre-
sent ﬁndings (both in vitro and
in vivo) support both theories of the
cause of peri-implantitis. Leaked Ti
ions from a dental implant could
transform into particles in the sur-
rounding tissue and become phagocy-
tized by macrophages, causing a
proinﬂammatory response, which, in
line with our in vitro results, is sub-
stantially enhanced in the presence of
microbial stimuli. If an inﬂammatory
condition is established in the peri-
implant mucosa and degradation of
bone that supports the implant starts,
colonization of bacteria on the
implant surface will take place and
the process might lead to peri-implant
diseases.
In conclusion, we show, for the
ﬁrst time, that Ti ions form particles
in physiological conditions that con-
ditions that induce activation and
secretion speciﬁcally of IL-1b. Analy-
ses of randomly selected mucosa
samples for metal content indicate
concentrations of Ti in vivo at levels
that could initiate activation and
secretion of IL-1b in vitro. Further
studies are needed to determine the
role of this ﬁnding for the initiation
and progress of peri-implantitis.
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